Some 100,000 people in the United States suffer from sickle cell disease. A new move by the FDA may soon hopefully break down at least some of the barriers people face in accessing appropriate treatment for the disease.
The New York Times reports that the FDA is lending its endorsement to two forms of gene editing therapy one for humans and another considered relatively conventional gene editing therapy.
Related posts:
- An STD called Donovanosis is spreading, if you haven’t heard of it we’ve got you covered
- Colonoscopy is still the most recommended screening for colorectal cancer, despite conflicting headlines and flawed interpretations of a new study
- New study unveils the places in our world most likely to become uninhabitable due to extreme heat before any where else
- Rite Aid one of the long accused pharmacy kingpins of America’s opioid crisis has filed for bankruptcy
Be First to Comment